ISCO Narrows Losses, Sales Up Amid Persistent Going Concern Doubts

TL;DR

**ISCO's Q3 profit is a mirage; the 'going concern' warning means this stock is a speculative gamble, not an investment.**

AI Summary

International Stem Cell Corporation (ISCO) reported a net income of $57 thousand for the three months ended September 30, 2025, a significant improvement from a net loss of $125 thousand in the same period of 2024. Product sales increased by 8.7% to $2.369 million for the quarter, up from $2.179 million in Q3 2024. For the nine months ended September 30, 2025, the company still posted a net loss of $70 thousand, though this is a substantial reduction from the $220 thousand net loss in the prior year. Total operating expenses remained relatively stable, increasing slightly to $2.275 million for the quarter from $2.269 million in Q3 2024. The company's accumulated deficit stood at $110.755 million as of September 30, 2025, and it continues to face a 'going concern' risk due to insufficient cash flow to fund operations for at least twelve months without additional financing. Cash decreased by $264 thousand during the nine months ended September 30, 2025, leaving $966 thousand in cash on hand. The related party note payable decreased from $3.395 million at December 31, 2024, to $3.305 million at September 30, 2025.

Why It Matters

ISCO's improved quarterly net income and increased product sales offer a glimmer of hope, but the persistent 'going concern' warning is a red flag for investors, indicating significant financial instability. The company's reliance on additional financing to sustain operations, coupled with an accumulated deficit of $110.755 million, suggests high risk. For employees, this uncertainty could impact job security, while customers might face concerns about long-term product availability if funding issues persist. In the competitive stem cell and anti-aging markets, ISCO's struggle to secure consistent profitability and funding could hinder its ability to innovate and compete effectively against larger, better-capitalized rivals.

Risk Assessment

Risk Level: high — The company explicitly states it has an accumulated deficit of approximately $110.8 million as of September 30, 2025, and 'does not have sufficient cash on hand to sustain operations for at least twelve months' without additional financing. This 'going concern' disclosure, coupled with a net cash outflow of $24 thousand from operating activities for the nine months ended September 30, 2025, indicates severe liquidity risk.

Analyst Insight

Investors should exercise extreme caution and consider this a highly speculative investment. Given the explicit 'going concern' warning and historical net losses, new investors should avoid ISCO until the company demonstrates a clear path to sustainable profitability and secures long-term financing. Existing investors should re-evaluate their position, understanding the significant risk of capital loss.

Financial Highlights

debt To Equity

N/A

revenue

$2.369 million

operating Margin

N/A

total Assets

N/A

total Debt

N/A

net Income

$57 thousand

eps

N/A

gross Margin

N/A

cash Position

$966 thousand

revenue Growth

+8.7%

Revenue Breakdown

Key Numbers

• $57 thousand — Net income (for the three months ended September 30, 2025, compared to a $125 thousand net loss in Q3 2024)
• $2.369 million — Product sales (for the three months ended September 30, 2025, an 8.7% increase from $2.179 million in Q3 2024)
• $70 thousand — Net loss (for the nine months ended September 30, 2025, a reduction from $220 thousand in the prior year)
• $110.755 million — Accumulated deficit (as of September 30, 2025, indicating significant historical losses)
• $966 thousand — Cash on hand (as of September 30, 2025, a decrease of $264 thousand from the beginning of the period)
• $3.305 million — Related party note payable (as of September 30, 2025, a slight decrease from $3.395 million at December 31, 2024)
• $24 thousand — Net cash used in operating activities (for the nine months ended September 30, 2025, indicating negative operational cash flow)
• 8,004,389 — Common Stock outstanding (as of November 7, 2025)

Key Players & Entities

• International Stem Cell Corporation (company) — registrant
• Lifeline Cell Technology, LLC (company) — wholly owned subsidiary for biomedical market
• Lifeline Skin Care, Inc. (company) — wholly owned subsidiary for anti-aging market
• Cyto Therapeutics Pty. Ltd. (company) — wholly owned subsidiary for therapeutic R&D
• SEC (regulator) — U.S. Securities and Exchange Commission
• Delaware (location) — state of incorporation
• San Diego, CA (location) — headquarters location
• Parkinson's disease (medical_condition) — target for clinical trials by Cyto Therapeutics
• Bloomberg (company) — publisher

FAQ

Risk Factors

• Going Concern Risk [high — financial]: The company faces a 'going concern' risk due to insufficient cash flow to fund operations for at least twelve months without additional financing. Cash decreased by $264 thousand during the nine months ended September 30, 2025, leaving $966 thousand in cash on hand.
• Accumulated Deficit [high — financial]: The company has a significant accumulated deficit of $110.755 million as of September 30, 2025, indicating substantial historical unprofitability.
• Dependence on Related Party Financing [medium — financial]: The company has a related party note payable of $3.305 million as of September 30, 2025. While this decreased slightly from $3.395 million at December 31, 2024, it highlights a reliance on related party obligations.

Industry Context

The stem cell industry is characterized by high research and development costs, long product development cycles, and significant regulatory hurdles. Companies in this sector often operate at a loss for extended periods due to these factors. Competition is intense, with both established biotechnology firms and emerging startups vying for market share and investment.

Regulatory Implications

As a biotechnology company, ISCO is subject to stringent regulations from bodies like the FDA. Compliance with these regulations is critical for product approval and market access. Any delays or failures in regulatory processes can significantly impact financial performance and future prospects.

What Investors Should Do

1. Monitor cash burn and future financing needs.
2. Evaluate the sustainability of revenue growth.
3. Assess the impact of the accumulated deficit.

Key Dates

• 2025-09-30: End of Q3 2025 — Reported net income of $57 thousand, a significant improvement from a net loss in the prior year. Product sales increased by 8.7% to $2.369 million.
• 2025-09-30: Balance Sheet Date — Accumulated deficit stood at $110.755 million. Cash on hand was $966 thousand. Related party note payable was $3.305 million.
• 2024-09-30: End of Q3 2024 — Reported a net loss of $125 thousand. Product sales were $2.179 million.

Glossary

Accumulated Deficit

The total cumulative net losses of a company that have not been offset by net income or other gains since its inception. (Indicates the company's long-term unprofitability, standing at $110.755 million as of September 30, 2025.)

Going Concern

A business's ability to continue operating for the foreseeable future, typically considered to be at least the next 12 months. (ISCO faces this risk due to insufficient cash flow, requiring additional financing to sustain operations.)

Related Party Note Payable

A debt obligation owed to an entity that has a close relationship with the reporting company, such as a major shareholder or management. (ISCO has a $3.305 million note payable to a related party, indicating a reliance on internal or closely associated financing.)

Year-Over-Year Comparison

Compared to the prior year's third quarter, ISCO has shown a marked improvement, moving from a net loss of $125 thousand to a net income of $57 thousand. Product sales also saw a healthy increase of 8.7%. However, for the nine-month period, the company still reports a net loss, albeit reduced. The accumulated deficit remains a significant concern, and the company continues to face 'going concern' risks due to its cash position and operating cash flow.

Filing Documents

• isco-20250930.htm (10-Q) — 2531KB
• isco-ex31_1.htm (EX-31.1) — 14KB
• isco-ex31_2.htm (EX-31.2) — 14KB
• isco-ex32_1.htm (EX-32.1) — 9KB
• isco-ex32_2.htm (EX-32.2) — 9KB
• 0001193125-25-280090.txt ( ) — 11699KB
• isco-20250930.xsd (EX-101.SCH) — 1056KB
• isco-20250930_htm.xml (XML) — 3056KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION Item 1. Condensed Consolidated Financial Statements (Unaudited) 3 Condensed Consolidated Balance Sheets as of September 30, 2025 (Unaudited) and December 31, 2024 3 Condensed Consolidated Statements of Operations for the three and nine months ended September 30, 2025 and 2024 (Unaudited) 4 Condensed Consolidated Statements of Changes in Redeemable Convertible Preferred Stock and Stockholders' Deficit for the three and nine months ended September 30, 2025 and 2024 (Unaudited) 5 Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2025 and 2024 (Unaudited) 7 Notes to Condensed Consolidated Financial Statements (Unaudited) 8 Item 2.

Management's Discussion and Analysis of Financial Condition and Results of Operations

Management's Discussion and Analysis of Financial Condition and Results of Operations 22 Item 3.

Quantitative and Qualitative Disclosures About Market Risk

Quantitative and Qualitative Disclosures About Market Risk 28 Item 4.

Controls and Procedures

Controls and Procedures 29

—OTHER INFORMATION

PART II—OTHER INFORMATION Item 1.

Legal Proceedings

Legal Proceedings 30 Item 1A.

Risk Factors

Risk Factors 30 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 30 Item 3. Defaults Upon Senior Securities 30 Item 4. Mine Safety Disclosures 30 Item 5. Other Information 30 Item 6. Exhibits 31

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Condensed Consolidated Financi al Statements

Item 1. Condensed Consolidated Financi al Statements International Stem Cell Corporation and Subsidiaries Condensed Consolida ted Balance Sheets (In thousands, except share and par value data) (Unaudited) September 30, December 31, 2025 2024 Assets Current assets: Cash $ 966 $ 1,230 Accounts receivable, net 1,015 1,058 Inventories 1,591 1,149 Prepaid expenses and other current assets 162 123 Total current assets 3,734 3,560 Non-current inventories 239 252 Property and equipment, net 192 257 Intangible assets, net 661 721 Right-of-use assets 425 352 Deposits and other assets 31 31 Total assets $ 5,282 $ 5,173 Liabilities, Redeemable Convertible Preferred Stock and Stockholders' Deficit Current liabilities: Accounts payable $ 265 $ 186 Accrued liabilities 452 527 Operating lease liabilities, current 383 330 Advances 250 250 Related party note payable 3,305 3,395 Total current liabilities 4,655 4,688 Operating lease liabilities, net of current portion 103 115 Total liabilities 4,758 4,803 Commitments and contingencies (Note 8) Series D redeemable convertible preferred stock, $ 0.001 par value; 50 shares authorized; 43 shares issued and outstanding; liquidation preference of $ 4,300 at September 30, 2025 and December 31, 2024 4,300 4,300 Stockholders' Deficit: Non-redeemable convertible preferred stock, $ 0.001 par value; 10,004,310 and 10,004,310 shares authorized; 5,254,310 and 5,254,310 shares issued and outstanding; liquidation preference of $ 9,823 and $ 9,811 at September 30, 2025 and December 31, 2024, respectively 5 5 Common stock, $ 0.001 par value; 120,000,000 shares authorized; 8,004,389 shares issued and outstanding at September 30, 2025 and December 31, 2024 8 8 Additional paid-in capital 106,966 106,742 Accumulated deficit ( 110,755 ) ( 110,685 ) Total stockholders

View Full Filing

View this 10-Q filing on SEC EDGAR